Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Combined With Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer
NCT01051765Phase 2Unknown
- Sponsor
- Peking University
- Start
- Aug 2009
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking University. Status: unknown.
02
Drugs
irinotecan
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT01051765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01051765.